R6890
Chemical compound
| R6890 | |
|---|---|
| Chemical structure of R6890 | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 119192-32-4 |
| PubChem | 65880 |
| DrugBank | |
| ChemSpider | 59292 |
| KEGG | D05892 |
R6890 is a chemical compound that has been studied for its potential pharmacological properties. It is known for its action as a selective serotonin receptor antagonist, particularly targeting the 5-HT2A receptor.
Chemical Structure[edit | edit source]
R6890 is chemically classified as a piperazine derivative. Its IUPAC name is 1-(2,3-dihydro-1H-inden-2-yl)-4-(3-chlorophenyl)piperazine. The compound features a piperazine ring, which is a common motif in many pharmacologically active compounds, linked to a chlorophenyl group and an indanyl moiety.
Pharmacology[edit | edit source]
R6890 acts primarily as a selective antagonist at the 5-HT2A receptor, a subtype of the serotonin receptor family. This receptor is implicated in various neurological processes, including mood regulation, perception, and cognition. By blocking this receptor, R6890 may influence these processes, although its precise effects in humans are not fully understood.
Potential Applications[edit | edit source]
The selective antagonism of the 5-HT2A receptor by R6890 suggests potential applications in the treatment of disorders such as schizophrenia, depression, and other conditions where serotonin dysregulation is a factor. However, further research is necessary to fully elucidate its therapeutic potential and safety profile.
Research and Development[edit | edit source]
R6890 has been the subject of various preclinical studies to assess its pharmacological properties and potential therapeutic uses. These studies typically involve in vitro assays and animal models to determine its efficacy and safety.
Related Compounds[edit | edit source]
R6890 is related to other piperazine derivatives that also target serotonin receptors. These compounds are often explored for their potential in treating psychiatric and neurological disorders.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
